Black Diamond Therapeutics, specializing in targeted cancer therapies, reported a significant financial turnaround in 2025 with net income of $22.4 million and operating income of $12.5 million, reversing prior multi-year losses. Its lead asset, silevertinib, progressed in Phase 2 trials for EGFR-mutant NSCLC and glioblastoma, supporting future growth. The outlicensing of BDTX-4933 to Servier diversifies risk and extends development reach. With strong liquidity through 2028, the company faces clinical, regulatory, and macroeconomic challenges but is positioned to capitalize on its MasterKey therapy platform.